Article type: Original Article

Longitudinal Validation of a Deep Learning Index for Aortic Stenosis Progression

Jiesuck Park,[a,b†] Jiyeon Kim,[c†] Yeonyee E. Yoon,[a,b,c*] Jaeik Jeon,[c] Seung-Ah Lee,[c,d] Hong-Mi Choi,[a,b] In-Chang Hwang,[a,b] Goo-Yeong Cho,[a,b] Hyuk-Jae Chang[c,d,e], Jae-Hyeong Park[f*]

[a]Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Republic of Korea

[b]Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea

[c]Ontact Health Inc., Seoul, Republic of Korea

[d]CONNECT-AI Research Center, Yonsei University College of Medicine, Seoul, Republic of Korea

[e]Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Republic of Korea

[f]Department of Cardiology, Internal Medicine, Chungnam National University Hospital, 282 Munhwa-ro, Jung-gu Daejeon, 35015, Republic of Korea

[†]The first two authors contributed equally to this work.

Running title: AI for Aortic Stenosis Progression

***Corresponding authors:**

Yeonyee E. Yoon, MD, PhD

Professor, Division of Cardiology, Cardiovascular Center

Seoul National University Bundang Hospital

82, 173 Beon-gil, Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

Phone: 82-31-787-7072

Email: yeonyeeyoon@snubh.org

And

Jae-Hyeong Park, MD, PhD

Department of Cardiology, Internal Medicine,

Chungnam National University Hospital,

282 Munhwa-ro, Jung-gu Daejeon, 35015, Republic of Korea

E-mail: jaehyeongpark@gmail.com

ABSTRACT

Aims Aortic stenosis (AS) is a progressive disease requiring timely monitoring and intervention. Transthoracic echocardiography (TTE) remains the gold standard for AS assessment, while deep learning (DL)-based approaches have emerged as promising tools for enhanced evaluation. This study examined the longitudinal changes in a previously developed DL-derived index for AS continuum (DLi-ASc; scaled 0 to 100) and its association with AS progression. Additionally, we evaluated its utility in identifying high-risk patients prone to progression to severe AS.

Methods and Results A total of 2,563 patients with follow-up TTE (8,053 TTEs) from two tertiary hospitals were included. DLi-ASc, generated from limited TTE views, was tracked over time. The longitudinal trends in AS severity showed a progressive shift toward advanced stages, with a corresponding increase in DLi-ASc (p for trend <0.001). DLi-ASc demonstrated positive correlations with conventional AS parameters, including AV maximal velocity (V_{max}) (Pearson correlation coefficients [PCC] = 0.68) and mean pressure gradient (mPG) (PCC = 0.69). Higher baseline DLi-ASc was associated with a faster AS progression rate (p for trend <0.001). Furthermore, baseline DLi-ASc was an independent predictor of progression to severe AS, with hazard ratios of 2.92, 2.45, and 2.67 per 10-score increase within 1-, 2-, and 3-year follow-up windows, respectively. A DLi-ASc threshold of 50 was identified as a threshold for rapid progression to severe AS.

Conclusion DLi-ASc increased in parallel with AS progression and independently predicted severe AS progression. These findings support its role as a non-invasive imaging-based digital marker for longitudinal AS monitoring and risk stratification.

Keywords: Aortic stenosis; artificial intelligence; echocardiography; progression

1. INTRODUCTION

Aortic stenosis (AS) is a progressive disease that worsens over time and is increasingly prevalent in aging populations.[1,2] Effective management requires timely monitoring and intervention. Transthoracic echocardiography (TTE) remains the gold standard for AS evaluation[3,4], but its reliance on multiple Doppler-derived parameters introduces variability and requires operator expertise for accurate image acquisition and interpretation. To enhance objectivity and scalability, artificial intelligence (AI) has been explored for AS assessment, primarily in two directions: (1) automating conventional AS evaluation and (2) predicting significant or severe AS using limited imaging data.[5-8]

In this context, we previously developed a novel deep learning (DL)-derived index for the AS continuum (DLi-ASc) that can quantify AS severity using limited TTE views – either parasternal long-axis (PLAX) or parasternal short-axis (PSAX) views.[5] Rigorous validation demonstrated its diagnostic accuracy and prognostic value, comparable to conventional AS parameters. However, its potential utility in predicting AS progression remains unexamined. We hypothesise that this DLi-ASc can facilitate not only the initial assessment of AS but also longitudinal follow-up, aiding in disease monitoring and potentially predicting progression rate.

This study aimed to evaluate temporal changes in the DLi-ASc in relation to AS progression using a longitudinal echocardiographic dataset. Specifically, we examined the temporal trajectory of DLi-ASc across different AS severity stages and its association with conventional echocardiographic parameters. Additionally, we assessed whether baseline DLi-ASc could stratify the risk of rapid progression to severe AS, providing a potential DL-based digital marker for risk prediction and clinical decision-making.

2. METHODS

2.1. Study Population

The study population was collected from two tertiary institutions in South Korea: Seoul National University Bundang Hospital (SNUBH, March 2006 to October 2024) and Chungnam National University Hospital (CNUH, February 2010 to October 2024). Patients who underwent at least two serial TTE examinations and were diagnosed with AS, either at the time of the initial TTE or during follow-up, were included. Since this study aimed to evaluate AS progression through various analyses, including progression to severe AS, patients with severe AS at baseline TTE were excluded. Consequently, 1,553 patients (4,850 TTE exams) were included from SNUBH, and 1,010 patients (3,203 TTE exams) were recruited from CNUH. This study was approved by the institutional review boards of the participating hospitals, with a waiver for informed consent due to its retrospective, observational design (SNUBH B-2302-808-101; CNUH 2024-11-019). The study adhered to the revision of the Declaration of Helsinki (2013).

2.2 Clinical and Echocardiographic Data Acquisition

All TTE examinations were performed by trained echocardiographers or cardiologists following contemporary guidelines[3,4] and interpreted by board-certified cardiologists who specialised in echocardiography. While all available TTE examinations for each patient were collected, for those who underwent aortic valve replacement during the follow-up period, only TTE data obtained before the procedure were included. AS severity metrics from each TTE were extracted from clinical reports used for the treatment decision-making.[3]

2.3. DL-Based AS Assessment Algorithm

The DL model used in this study has been previously described and is integrated into an AI-enhanced AS evaluation system (USfeat_valve.ai, Ontact Health, Korea).[5] Briefly, the model utilises a 3-dimensional (3D) convolutional neural network (r2plus1d18) to analyse TTE videos, generating a continuous severity score, the DLi-ASc (range 0–100). This index quantifies AS severity based on limited TTE views - specifically the PLAX and PSAX views at the aortic valve (AV) level. To enhance the reliability of AS severity evaluation, the model incorporates ordered label mapping and multi-task learning, leveraging auxiliary tasks to predict key TTE parameters such as AV maximal velocity (V_{max}), mean pressure gradient (mPG), and AV area (AVA). For each patient, if multiple PLAX or PSAX views were available, DLi-ASc was first averaged within each view type (PLAX and PSAX separately) and then averaged across both views. If only one view type was available, its score was used. The DLi-ASc was generated for all baseline and follow-up TTE examinations included in this study. The DL model successfully generated DLi-ASc for all cases, ensuring full data availability for longitudinal analysis with no exclusions due to model processing failure.

2.4. Statistical Analysis

Clinical data are described in the study as the median with interquartile range (IQR) or mean with 95% confidence interval (CI) for continuous variables and as percentage numbers for factorial variables. Baseline characteristics were compared between the cohorts, with significant differences determined using the Kruskal-Wallis test and Chi-square test, as appropriate.

The temporal progression of AS severity was illustrated using a proportional stacked bar plot, showing the relative distribution of AS stage (normal AV, AV sclerosis, mild AS, moderate AS, and severe AS) over follow-up years, with p for trend calculated using the Chi-

square test. The temporal distribution of DLi-ASc across the baseline AS severity stage was visualised using ridge density plots. Trends in mean DLi-ASc were analysed using linear regression models. The association between DLi-ASc and conventional AS parameters, such as AV V_{max} and AV mPG was evaluated using scatterplots with Pearson correlation coefficients (PCC).

The annualised progression rate of AV V_{max} and AV mPG was calculated to investigate the relationship between baseline DLi-ASc and AS progression rate in patients with a follow-up duration of ≥1 year. The annualised rate for each parameter was determined using the formula: (final measurement - baseline measurement) / follow-up duration.[9] The association between baseline DLi-ASc and the annualised changes in AV V_{max} and AV mPG was evaluated using violin plots, illustrating the distribution of AS progression rate across different baseline DLi-ASc categories (<25, 25 to <50, 50 to <75, and ≥75). Additionally, a spline curve was fitted to visualise the trend between the baseline DLi-ASc and AS progression rate. Further subgroup analysis was performed by categorizing patients into rapid (annualised AV V_{max} > 0.3 m/s/year) and slow (≤ 0.3 m/s/year) progression groups[10] and their baseline DLi-ASc values were compared to assess its association with progression rate.

We assessed the predictive performance of baseline DLi-ASc for progression to severe AS. Progression to severe AS was identified based on TTE reports, with the earliest TTE showing severe AS designated as the event date. Patients who did not progress to severe AS were censored at their latest TTE date. Given that the frequency and timing of follow-up TTE are subject to clinical discretion and influenced by patient symptoms and treatment plans, follow-up TTE exams were categorised into 1-, 2-, and 3-year intervals from baseline TTE. This approach was purposed to provide a practical assessment of the predictive value of DLi-ASc for severe AS progression within specific time windows. To evaluate the prognostic value

of baseline DLi-ASc, both univariable and multivariable Cox proportional hazard regression analyses were performed to estimate the hazard ratio (HR) for progression to severe AS per 10-score increase in DLi-ASc. Multivariable models were adjusted for age, sex, estimated glomerular filtration rate (eGFR), and baseline AS severity. To assess the discriminative performance, receiver operating characteristic (ROC) curve analysis was performed, and the area under the curve (AUC) was calculated for severe AS progression within 1-, 2-, and 3-year follow-up intervals. We compared a clinical model (age, sex, eGFR, and baseline AS severity) with an enhanced model incorporating DLi-ASc. DeLong's test was used to determine whether the inclusion of DLi-ASc significantly improved model performance.

To assess the robustness of our findings, a sensitivity analysis was conducted by excluding all patients whose TTE exams were used in the training phase of the DLi-ASc model.[5] In this subset (1,227 patients; 3,933 TTE exams), the same analyses were repeated, including longitudinal DLi-ASc trends, association with AS progression rate, and predictive performance for severe AS progression.

All statistical analyses were performed using R software (v4.3.2; R Development Core Team, Vienna, Austria). Two-sided p-values <0.05 were considered statistically significant.

2.5. Funding

The study was supported by a grant from the Institute of Information & communications Technology Planning & Evaluation (IITP) funded by the Korea government (Ministry of Science and ICT); and the Medical AI Clinic Program through the NIPA funded by the MSIT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

3. RESULTS

3.1. Baseline Characteristics

A total of 2,563 patients (median age 76 years, interquartile range [IQR] 69–82; 45.7% male) with 8,053 TTE examinations were included in this study. (**Table 1)** Each patient underwent a median of three TTE examinations (IQR 2–4), with no significant difference between two cohorts. In the pooled cohort, baseline AS severity was categorised as normal AV (8.1%), AV sclerosis (18.1%), mild AS (54.4%), and moderate AS (19.4%), with significant differences between the cohorts ($P < 0.001$). Compared to CNUH, SNUBH cohort had a lower proportion of normal AV and AV sclerosis but a higher proportion of mild AS, while the proportion of moderate AS was similar between two cohorts. As a result, DLi-ASc was slightly higher in SNUBH, with a median 50 (IQR 47–53), compared to 49 (IQR 44-52) in CNUH ($p<0.001$)

3.2. Temporal Changes in AS Severity and Corresponding DLi-ASc Distributions

In the pooled cohort, the median follow-up duration from baseline TTE was 43.5 months (IQR 22.4–76.6 months, range 0.1–188.6 months). As shown in **Figure 1**, the distribution of AS stages demonstrated a progressive shift toward more advanced stages over time, with increasing proportions of moderate and severe AS as the follow-up period extended (p for trend <0.001). The annualised progression rate of V_{max} and mPG were 0.14 m/s/year (95% CI 0.13–0.15) and 2.04 mmHg/year (95% CI 1.88–2.20) in pooled cohort, 0.11 m/s/year (0.10–0.12) and 1.52 mmHg/year (1.37–1.67) in mild AS, and 0.21 m/s/year (0.19–0.23) and 4.05 mmHg/year (3.63–4.47) in moderate AS.

A similar trend was observed in DLi-ASc changes over time. The annualised rate of DLi-ASc was 1.46 (95% CI 1.35–1.57) in pooled cohort, 1.14 (1.01–1.27) in mild AS, and 2.57 (2.18–2.96) in moderate AS. The DLi-ASc increase across baseline AS severity grades is

illustrated in **Figure 2**. At baseline, the median (IQR) DLi-ASc values for each stage were: normal 44 (37–47), AV sclerosis 48 (44–50), mild AS 49 (47–51), and moderate AS 56 (52–61). These values increased over time, reaching 47 (42–50), 50 (48–53), 51 (49–54), and 60 (56–67) at 3 years, and 49 (45–51), 50 (48–53), 53 (50–60), and 63 (56–69) at 6 years (**Supplemental Result 1**). The increase in DLi-ASc was statistically significant across all AS stages (p for trend =0.002 for normal AV and <0.001 in all other groups) (**Figure 2**). For complementary visualisation of individual-level DLi-ASc trajectories, subject-level connected line plots are also provided (**Supplemental Results 2**). These findings align with **Figure 1**, reinforcing DLi-ASc's potential as a surrogate marker for monitoring long-term AS progression.

While DLi-ASc generally increased over time, transient decreases were observed in 33.6% of consecutive TTE pairs, mostly when the follow-up interval was short (median 16 months). When comparing only the first and last TTEs (median 43 months), the proportion showing a net decrease dropped to 22.6%, again predominantly in cases with shorter follow-up. Notably, the absolute magnitude of DLi-ASc change increased with longer interscan intervals (**Supplemental Results 3**), suggesting that short-term decreases are more likely due to technical or image-related variability than true biological improvement.

3.3 Association of DLi-ASc with Conventional AS Parameters

Analysis of all TTE examinations across the study cohort revealed a significant positive correlation between DLi-ASc and AV V_{max} (PCC = 0.68, 95% CI: 0.67–0.70, p<0.001), indicating that higher DLi-ASc corresponds to increased AV V_{max}. (**Figure 3**) Similarly, a robust association was observed between DLi-ASc and AV mPG, with PCC = 0.69 (95% CI: 0.68–0.70, p<0.001), suggesting that rising DLi-ASc values are linked to higher AV pressure

gradient.

3.4. Association of Baseline DLi-ASc with AS Progression Rate

When analyzing the annualised AS progression rate stratified by baseline DLi-ASc categories (**Figure 4**), significant positive trends were observed, with higher baseline DLi-ASc associated with faster AV V_{max} and AV mPG progression (all p for trend <0.001). Additionally, patients with rapid AS progression (annualised AV V_{max} >0.3 m/s/year) had significantly higher baseline DLi-ASc compared to those with slower progression (53 [50–57] vs. 49 [47–52]; p <0.001).

3.5. Predictive Performance of DLi-ASc of Severe AS Progression

Spline curves demonstrated a non-linear association between baseline DLi-ASc and the estimated HRs for severe AS progression. (**Figure 5**) The risk remained low and stable at lower DLi-ASc values but rose sharply beyond a threshold of approximately 50, indicating a marked increase in the risk of rapid AS progression. This pattern was consistently observed across the 1-year, 2-year, and 3-year time windows. After adjustment for age, sex, eGFR, and baseline AS severity, multivariable Cox regression analysis was confirmed that baseline DLi-ASc was an independent predictor of severe AS progression. A 10-score increase in DLi-ASc associated with a significantly elevated risk, with HRs 2.92 (95% CI: 2.15–3.96) for progression within 1 year, 2.45 (95% CI: 1.91–3.14) within 2 years, and 2.67 (95% CI: 2.17-3.29) within 3 years. (**Figure 5**)

To evaluate the incremental prognostic value of DLi-ASc over conventional clinical factors, we compared two models using ROC curve analysis: a clinical model (age, sex, eGFR, and baseline AS severity) and an enhanced model with the addition of DLi-ASc. The inclusion of DLi-ASc significantly improved discrimination for severe AS progression across all time

windows (1 year: AUC 0.92 to 0.95, $p<0.001$; 2 years: 0.89 to 0.92, $p<0.001$; 3 years: 0.87 to 0.90, $p<0.001$). (**Supplemental Results 4**)

3.6. Sensitivity Analysis

A sensitivity analysis was performed after excluding all patients whose TTE exams were used in the training phase of the DLi-ASc model. Key analyses were repeated in this subset, and the results were consistent with those of the full cohort. Detailed findings are provided in the **Supplemental Results 5**.

4. DISCUSSION

In this study, we further evaluated the clinical utility of DLi-ASc, a DL-derived quantitative AS severity metric previously developed for accurate AS. Using a large, longitudinal dataset, we demonstrated its potential for AS monitoring. Longitudinal tracking showed that DLi-ASc increased in parallel with the natural progression of AS, supporting its role as a dynamic marker of disease severity. When baseline and follow-up data were pooled, DLi-ASc strongly associated with conventional AS parameters (AV V_{max} and mPG), reinforcing its alignment with established AS severity metrics. More importantly, higher baseline DLi-ASc was associated with faster AS progression and independently predicted progression to severe AS across different time windows. These findings highlight DLi-ASc's potential as a risk stratification tool for identifying patients at elevated risk of rapid AS progression.

The role of AI in TTE is evolving. Early applications focused on automating manual measurements, enhancing accuracy and reproducibility. With most TTE parameters now capable of automation, AI has expanded to disease severity assessment, as seen in diastolic dysfunction[11,12] and AS evaluation.[8] More recently, AI has progressed beyond parameter-based analysis to DL-based direct TTE video analysis, aiming to mimic expert visual assessment.[5-7,11] In our previous study, we developed a DL model capable of accurately assessing AS severity using PLAX and/or PSAX views.[5] The strength of this DL-based index lies in its ability to mimic visual analysis while providing a quantitative digital marker. Our prior work validated this approach in a large cross-sectional cohort, confirming its diagnostic performance. However, while the model was designed to reflect the AS disease continuum, whether DLi-ASc would increase in parallel with AS progression over time remained unclear.

While previous studies have introduced DL-based indices[5-7], this study is the first to validate a progressive increase in a DL-derived AS marker over serial follow-up examinations.

Oikonomou et al. developed a DL-based index (Digital AS Severity Index [DASSi]) derived from PLAX view to predict severe AS[6] and reported its potential to forecast AS progression.[13] However, their study did not evaluate whether the DL index itself increased over time in parallel with AS progression. A key strength of our study is demonstrating a consistent increase in DLi-ASc over time using longitudinal data, leveraging the natural progression of AS as a reference. Moreover, we demonstrated that DLi-ASc increases as patients with AS advance to severe stages and individuals with initially normal AV develop AS, highlighting its ability to capture early disease progression. Notably, baseline DLi-ASc values for patients with normal functioning AV or AV sclerosis were higher than those reported in our prior study [5], likely due to differences in cohort composition. While the previous study included individuals without AS, the current study enrolled patients who eventually developed AS during follow-up. Therefore, the elevated baseline DLi-ASc in these groups may reflect early pathological changes rather than misclassification. By utilising a large longitudinal cohort, this study bridges an important gap, establishing DLi-ASc as a valuable tool not just for AS detection but also for follow-up monitoring.

Furthermore, this study demonstrated that DLi-ASc is associated with AS progression rate and serves as an independent predictor of severe AS progression risk. While AVA, V_{max}, and mPG remain the gold standard for AS severity assessment, DLi-ASc offers a continuous, DL-driven risk metric that may provide additional predictive value. Notably, these findings support the potential of DLi-ASc in guiding personalised surveillance strategies. Given the steep rise in risk beyond DLi-ASc 50, it may be reasonable to implement differentiated follow-up strategies rather than applying uniform monitoring intervals to all AS patients. In addition, although current AS management primarily focuses on AV replacement after severe AS develops, the ability to quantify AS progression with DLi-ASc could become particularly

valuable if medical treatment to slow AS progression becomes available in the future. In such a scenario, DLi-ASc could serve as a quantitative marker for tracking disease progression and identifying patients at higher risk for rapid progression who may benefit from earlier or more aggressive intervention. Despite its promise, clinical implementation of AI-based tools like DLi-ASc may be influenced by factors such as accessibility, cost, and integration into existing echocardiographic workflows. Future efforts should focus on optimising deployment strategies to ensure widespread clinical applicability.

This study has several limitations. First, the retrospective nature of data collection introduces inherent constraints. Notably, TTE intervals were not standardised, limiting the ability to precisely quantify the annual rate of AS progression either based on conventional AS parameters or DLi-ASc. Nevertheless, the AS progression rates observed in this study fall within the range reported in prospective studies.[9] Although the annualised progression rate of Vmax (0.19m/sec/year) and mPG (4.10 mmHg/year) from a prior meta-analysis were slightly higher than those observed in our study, this discrepancy likely reflects the inclusion of patients with normal AV and AV sclerosis at baseline in our cohort. Importantly, the progression rates observed in patients with mild and moderate AS were consistent with those reported in prior prospective studies, supporting the validity of our findings despite the retrospective study design. For sure, future prospective studies with standardised follow-up protocols could further validate the value of DLi-ASc in assessing the temporal dynamics of AS progression in a more systematic manner and may also enable advanced modeling approaches – such as trajectory clustering or unsupervised pattern recognition – to explore distinct AS progression phenotypes. Second, the dataset was derived from two tertiary hospitals in South Korea, where TTE examinations were performed by specialised cardiologists with expertise in echocardiography. While this ensures high-quality imaging and reliable data, it also raises concerns about

generalizability to resource-limited settings, where non-experts often perform TTE. Since DLi-ASc was developed to enhance AS assessment across diverse clinical environments, further studies are needed to evaluate its performance in settings with limited echocardiographic expertise. Additionally, while DL analysis was successfully performed in all cases and DLi-ASc generally increased over time, transient decreases were occasionally observed, particularly with short follow-up intervals. These likely reflect technical or image-related variability, representing an inherent limitation of DL-based image analysis. Finally, to ensure broader generalizability, additional research in diverse racial and geographic populations is essential to establish the clinical applicability and real-world implications of DLi-ASc.

5. CONCLUSION

This study demonstrated the utility of DLi-ASc for longitudinal AS monitoring and risk stratification. DLi-ASc increased over time in parallel with AS progression and showed a strong association with conventional AS parameters. Importantly, higher baseline DLi-ASc independently predicted progression to severe AS, with a sharp increase beyond a threshold of 50. These findings support DLi-ASc as a noninvasive imaging biomarker for tracking and identifying high-risk patients for AS progression.

Contributors

All authors contributed equally to this study. All authors have read and approved the final version of the manuscript. J.P, J.K, and Y.E.Y verified the underlying data of the current study.

Data Sharing Statement

Please contact the corresponding author (yeonyeeyoon@gmail.com) to request the minimal anonymised dataset. Researchers with additional inquiries about the deep learning model developed in this study are also encouraged to reach out to the corresponding author.

Declaration of Interests

Y.E.Y, J.J., J.K., and S.A.L. are currently affiliated with Ontact Health, Inc. J.J., J.K., and S.A.L are co-inventors on a patent related to this work filed by Ontact Health (Method For Providing Information On Severity Of Aortic Stenosis And Device Using The Same). H.J.C., and Y.E.Y hold stock in Ontact Health, Inc. The other authors have no conflicts of interest to declare.

Acknowledgements

This work was supported by a grant from the Institute of Information & communications Technology Planning & Evaluation (IITP) funded by the Korea government (Ministry of Science and ICT) (No.2022000972, Development of a Flexible Mobile Healthcare Software

Platform Using 5G MEC); and the Medical AI Clinic Program through the NIPA funded by the MSIT. (Grant No.: H0904-24-1002).

REFERENCES

1 Owens DS, Bartz TM, Buzkova P, Massera D, Biggs ML, Carlson SD, et al. Cumulative burden of clinically significant aortic stenosis in community-dwelling older adults. *Heart*. 2021;107:1493–1502.

2 Yi B, Zeng W, Lv L, Hua P. Changing epidemiology of calcific aortic valve disease: 30-year trends of incidence, prevalence, and deaths across 204 countries and territories. *Aging*. 2021;13:12710–12732.

3 Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2021;77:e25–e197.

4 Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, et al. Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2017;30:372–392.

5 Park J, Kim J, Jeon J, Yoon YE, Jang Y, Jeong H, et al. Artificial intelligence-enhanced comprehensive assessment of the aortic valve stenosis continuum in echocardiography. *EBioMedicine*. 2025;112:105560.

6 Holste G, Oikonomou EK, Mortazavi BJ, Coppi A, Faridi KF, Miller EJ, et al. Severe aortic stenosis detection by deep learning applied to echocardiography. *Eur Heart J*. 2023;44:4592–4604.

7 Wessler BS, Huang Z, Long GM Jr, Pacifici S, Prashar N, Karmiy S, et al. Automated Detection of Aortic Stenosis Using Machine Learning. *J Am Soc Echocardiogr*. 2023;36:411–420.

8 Krishna H, Desai K, Slostad B, Bhayani S, Arnold JH, Ouwerkerk W, et al. Fully Automated Artificial Intelligence Assessment of Aortic Stenosis by Echocardiography. *J Am Soc Echocardiogr*. 2023;36:769–777.

9 Willner N, Prosperi-Porta G, Lau L, Nam Fu AY, Boczar K, Poulin A, et al. Aortic Stenosis Progression: A Systematic Review and Meta-Analysis. *JACC Cardiovasc Imaging*. 2023;16:314–328.

10 Benfari G, Nistri S, Marin F, Cerrito LF, Maritan L, Tafciu E, et al. Excess Mortality Associated with Progression Rate in Asymptomatic Aortic Valve Stenosis. *J Am Soc Echocardiogr*. 2021;34:237–244.

11 Chen X, Yang F, Zhang P, Lin X, Wang W, Pu H, et al. Artificial Intelligence-Assisted Left Ventricular Diastolic Function Assessment and Grading: Multiview Versus Single View. *J Am Soc Echocardiogr*. 2023;36:1064–1078.

12 Park J, Jeon J, Yoon YE, Jang Y, Kim J, Jeong D, et al. Artificial intelligence-enhanced automation of left ventricular diastolic assessment: a pilot study for feasibility, diagnostic validation, and outcome prediction. *Cardiovasc Diagn Ther*. 2024;14:352–366.

13 Oikonomou EK, Holste G, Yuan N, Coppi A, McNamara RL, Haynes NA, et al. A Multimodal Video-Based AI Biomarker for Aortic Stenosis Development and Progression. *JAMA Cardiol*. 2024;9:534–544.

Table 1. Clinical Characteristics

	Overall (n=2,563)	SNUBH (n=1,553)	CNUH (n=1,010)	P for difference
Age	76 (69–82)	77 (71–82)	74 (67–80)	<0.001
Male	1,172 (45.7)	706 (45.5)	466 (46.1)	0.767
Female	1,391 (54.3)	847 (54.5)	544 (53.9)	
BSA	1.6 (1.5–1.8)	1.7 (1.5–1.8)	1.6 (1.5–1.8)	0.001
Baseline AS Severity				<0.001
Normal	207 (8.1)	4 (0.3)	203 (20.1)	
AV Sclerosis	464 (18.1)	179 (11.5)	285 (28.2)	
Mild AS	1,394 (54.4)	1,071 (69.0)	323 (32.0)	
Moderate AS	498 (19.4)	299 (19.3)	199 (19.7)	
Baseline DLi-ASc	49 (46–52)	50 (47–53)	49 (44–52)	<0.001
Follow-up, months	43.5 (22.4–76.6)	36.1 (19.5–63.6)	59.0 (28.6–99.0)	<0.001
No. of TTEs	8,053	4,850	3,203	
No. of TTE FU	3 (2–4)	3 (2–4)	3 (2–4)	0.183
At least 3 exams	1,382 (53.9)	822 (52.9)	560 (55.4)	0.227
At least 4 exams	709 (27.7)	420 (27.0)	289 (28.6)	0.411

Values are given as numbers (percentage) or median (interquartile range).
Abbreviations: AS, aortic valve stenosis; AV, aortic valve; BSA, body surface area; CNUH, Chungnam National University Hospital; DLi-ASc, deep learning-derived index for the AS continuum; FU, follow-up; SNUBH, Seoul National University Bundang Hspital; TTE, transthoracic echocardiography.

FIGURE LEGENDS

Figure 1. Temporal Progression of AS Severity Over Follow-Up Years

AS = aortic stenosis, AV = aortic valve



Figure 2. Temporal Trends in DLi-ASc Across Baseline AS Severity Categories

AS = aortic stenosis; DLi-ASc = deep learning-derived index for the AS continuum.



Figure 3. Association of DLi-ASc with Conventional AS Parameters

See abbreviations in Figure 2.



Figure 4. Association Between Baseline DLi-ASc and Annualised AS Progression Rate

See abbreviations in Figure 2.



Figure 5. Association Between Baseline DLi-ASc and Risk of Severe Aortic Stenosis Progression: Spline Curves and Adjusted Hazard Ratios Over 1-, 2-, and 3-Year Intervals

See abbreviations in Figure 2. CI = confidence interval; HR = hazard ratio.



Progression to Severe AS	Unadjusted HR (95% CI) per 10-score increase in DLi-ASc	Adjusted HR (95% CI) per 10-score increase in DLi-Asc
Within 1 yr	5.49 (4.39-6.88)	2.92 (2.15-3.96)
Within 2 yr	5.02 (4.19-6.02)	2.45 (1.91-3.14)
Within 3 yr	5.19 (4.45-6.05)	2.67 (2.17-3.29)